What Science Actually Knew About Medical Cannabis in 2001
A comprehensive review found strong evidence for cannabinoids in nausea and appetite stimulation, emerging evidence for pain and spasticity, but argued that oral or rectal delivery was preferable to smoking.
Quick Facts
What This Study Found
THC and several analogues showed significant therapeutic benefits for nausea, vomiting, and appetite stimulation in patients with wasting syndrome. Recent evidence demonstrated analgesic and anti-spasticity effects that the author considered likely to become clinically useful.
However, cannabinoid effects on intraocular pressure in glaucoma and bronchodilation in asthma were not sufficiently strong, long-lasting, or reliable for therapeutic use. Cannabidiol showed promising anticonvulsant effects warranting further clinical trials.
The author argued that for all established and probable future uses, pure cannabinoids administered orally, rectally, or parenterally were effective and avoided the risks of chronic airway inflammation and upper respiratory cancer associated with smoking crude cannabis.
Key Numbers
THC doses of 5-10 mg were referenced for therapeutic applications. The review covered multiple conditions but did not provide pooled statistical analyses.
How They Did This
This was a narrative review that assessed the literature on therapeutic uses of cannabis and cannabinoids. Studies were evaluated by design type, data quality, independent replication, effect size, comparison with other treatments, and adverse effects. Results were compared with major international reviews from the preceding five years.
Why This Research Matters
This review provided one of the more balanced and thorough assessments of the medical cannabis evidence base at the time. By sorting conditions into those with strong evidence (nausea, appetite), emerging evidence (pain, spasticity), and weak evidence (glaucoma, asthma), it helped establish a framework for prioritizing clinical research that largely held up over subsequent decades.
The Bigger Picture
Many of this review's conclusions have been validated by subsequent research. Cannabinoids are now approved for chemotherapy-induced nausea (dronabinol, nabilone) and appetite stimulation. Pain and spasticity indications have gained regulatory approvals in some jurisdictions. The prediction about new synthetic analogues with better therapeutic profiles has been partially realized.
What This Study Doesn't Tell Us
As a narrative review rather than a systematic review or meta-analysis, the study selection and interpretation reflected the author's judgment. Long-term pharmacokinetic data and drug interaction information were acknowledged as major gaps. The review predated many of the large clinical trials conducted in subsequent years.
Questions This Raises
- ?Have non-smoked cannabis delivery methods proven sufficient for patient populations, or has smoking remained common despite these concerns?
- ?Has the development of synthetic analogues with reduced psychoactivity met the predictions made in this review?
Trust & Context
- Key Stat:
- Strong evidence for nausea/appetite; emerging for pain/spasticity; weak for glaucoma/asthma
- Evidence Grade:
- This is a comprehensive narrative review comparing findings across multiple international reviews, providing moderate-level evidence through synthesis.
- Study Age:
- Published in 2001, this review predated many of the landmark clinical trials on cannabinoids for pain and spasticity conducted in subsequent years.
- Original Title:
- Medicinal use of cannabis: history and current status.
- Published In:
- Pain research & management, 6(2), 80-91 (2001)
- Authors:
- Kalant, H
- Database ID:
- RTHC-00108
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is smoking cannabis the best way to use it medically?
This review argued that oral, rectal, or injectable cannabinoids were preferable to smoking because they avoided respiratory risks while maintaining therapeutic effectiveness. This view has influenced the development of non-smoked medical cannabis products.
Why was the evidence for cannabis and glaucoma considered weak?
While cannabinoids can lower intraocular pressure, the effect was not strong enough, long-lasting enough, or reliable enough to serve as a practical treatment compared to existing glaucoma medications.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- blunts-vs-joints-vs-spliffs-difference
- how-to-tell-if-weed-is-moldy
- thc-patches-suppositories-topicals-explained
- dry-herb-vape-vs-oil-vape-vs-disposable
- thc-and-muscle-relaxers-combining
- cannabis-and-migraines-prevention-treatment
- cannabis-and-endometriosis-thc-pain
- cannabis-and-menstrual-cramps-period-pain
Cite This Study
https://rethinkthc.com/research/RTHC-00108APA
Kalant, H. (2001). Medicinal use of cannabis: history and current status.. Pain research & management, 6(2), 80-91.
MLA
Kalant, H. "Medicinal use of cannabis: history and current status.." Pain research & management, 2001.
RethinkTHC
RethinkTHC Research Database. "Medicinal use of cannabis: history and current status." RTHC-00108. Retrieved from https://rethinkthc.com/research/kalant-2001-medicinal-use-of-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.